Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Methodological quality of randomised controlled trials in burns care. A systematic review

Danilla S, Wasiak J, Searle S, Arriagada C, Pedreros C, Cleland H, Spinks A

(2009), Burns, 35(7), 956-61

Are we ready for the next big thing?

Cleland HJ

(2009), Med J Aust, 191(7), 412-3

End-of-life decision making – where have all the surgeons gone?

Cleland H, Mahar P

(2009), ANZ J Surg, 79(12), 865-6

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib

Watson AJ, Middleton MR, McGown G, Thorncroft M, Ranson M, Hersey P, McArthur G, Davis ID, Thomson D, Beith J, Haydon A, Kefford R, Lorigan P, Mortimer P, Sabharwal A, Hayward O, Margison GP

(2009), Br J Cancer, 100(8), 1250-6

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

Thürlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF, Castiglione-Gertsch M, Coates AS, Goldhirsch A

(2009), Breast Cancer Res Treat, 113(1), 137-44

Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group

Gianni L, Gelber S, Ravaioli A, Price KN, Panzini I, Fantini M, Castiglione-Gertsch M, Pagani O, Simoncini E, Gelber RD, Coates AS, Goldhirsch A

(2009), Eur J Cancer , 45(4), 561–71

Patients' views on decision making in advanced cancer

Philip J, Gold M, Schwarz M, Komesaroff P

(2009), Palliat Support Care, 7(2), 181-5

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E,Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group

(2009), Breast Cancer Res Treat, 116(3), 491-500

What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?

Olver IN, Haines IE

(2009), Med J Aust, 190(2), 74-7

The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer

Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ

(2009), Fam Cancer, 8(4), 299-305

An Australian clinical perspective: management of hormone refractory (androgen-independent) prostate cancer

Hovey E, Marx G, Kneebone A, Patel M, Shapiro J

(2009), Asia-Pacific J Oncol Hematol, 1(1), 82-3

Are guidelines on use of colony-stimulating factors in solid cancers flawed?

Haines IE, Olver I

(2009), Intern Med J, 39(4), 259-62

A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia

Haines I, Elliott P, Stanley R

(2009), Intern Med J, 39(4), 269-71

Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer

Giobbie-Hurder A, Price KN, Gelber RD; International Breast Cancer Study Group; BIG 1-98 Collaborative Group

(2009), Clin Trials, 6(3), 272-87

Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer

Bell RJ, Lijovic M, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Davis SR

(2009), J Womens Health, 18(12), 1975-80

How do you monitor patients on azathioprine/6-mercaptopurine?

Sparrow MP

(2009), In: Rubin DT, Friedman S, Farraye FA (eds) Curbside Consultations in IBD: 49 Clinical Questions, SLACK Incorporated, USA, Chapter 9, 39-44

Characterization of inflammatory bowel disease with urinary metabolic profiling

Williams HR, Cox IJ, Walker DG, North BV, Patel VM, Marshall SE, Jewell DP, Ghosh S, Thomas HJ, Teare JP, Jakobovits S, Zeki S, Welsh KI, Taylor-Robinson SD,Orchard TR

(2009), Am J Gastroenterol, 104(6), 1435-44

Optimizing conventional therapies for inflammatory bowel disease

Sparrow MP, Irving PM, Hanauer SB

(2009), Curr Gastroenterol Rep, 11(6), 496-503

Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial

Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group

(2009), Hepatology, 50(4), 1045-55

Feasibility of video capsule endoscopy in the management of children with peutz-jeghers syndrome: a blinded comparison with barium enterography for the detection of small bowel polyps

Postgate A, Hyer W, Phillips R, Gupta A, Burling D, Bartram C, Marshall M, Taylor S, Brown G, Schofield G, Bassett P, Spray C, Fitzpatrick A, Fraser C, Latchford A

(2009), J Pediatr Gastroenterol Nutr, 49(4), 417-23

553 554 555 556 557